In this review:
This publication is intended as an educational resource for healthcare professionals, particularly those involved in the assessment and management of patients with severe asthma. It discusses the pathophysiology and burden of severe asthma, with a focus on the eosinophilic phenotype. It reviews strategies for assessment and management of severe eosinophilic asthma, in particular the role of anti-IL-5 therapy. The publication has been commissioned by GlaxoSmithKline NZ Limited.
Download PDF